Biocon is currently trading at Rs. 289.95, up by 4.00 points or 1.40% from its previous closing of Rs. 285.95 on the BSE.
The scrip opened at Rs. 299.70 and has touched a high and low of Rs. 299.70 and Rs. 288.20 respectively. So far 290948 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 5 has touched a 52 week high of Rs. 341.43 on 25-Jan-2019 and a 52 week low of Rs. 211.30 on 20-Aug-2019.
Last one week high and low of the scrip stood at Rs. 299.70 and Rs. 268.85 respectively. The current market cap of the company is Rs. 34800.00 crore.
The promoters holding in the company stood at 60.67%, while Institutions and Non-Institutions held 20.76% and 18.58% respectively.
Biocon and Mylan NV have launched Ogivri (trastuzumab-dkst), a biosimilar to Herceptin (trastuzumab) in US. Ogivri is available in a 420 mg multi-dose vial and a 150 mg single-dose vial in order to provide patient dosing and treatment flexibility.
Ogivri was the first biosimilar trastuzumab approved by the US Food and Drug Administration (USFDA) and unanimously recommended by the USFDA Oncologic Drugs Advisory Committee (ODAC).
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient’s worldwide.